- Home
- HDL vs TNGX Comparison
HDL vs TNGX Comparison
Compare HDL & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HDL
- TNGX
- Stock Information
- Founded
- HDL 2016
- TNGX 2014
- Country
- HDL Singapore
- TNGX United States
- Employees
- HDL N/A
- TNGX N/A
- Industry
- HDL Restaurants
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- HDL Consumer Discretionary
- TNGX Health Care
- Exchange
- HDL Nasdaq
- TNGX Nasdaq
- Market Cap
- HDL 1.1B
- TNGX 1.0B
- IPO Year
- HDL 2024
- TNGX N/A
- Fundamental
- Price
- HDL $17.77
- TNGX $8.18
- Analyst Decision
- HDL
- TNGX Strong Buy
- Analyst Count
- HDL 0
- TNGX 6
- Target Price
- HDL N/A
- TNGX $10.80
- AVG Volume (30 Days)
- HDL 1.1K
- TNGX 4.5M
- Earning Date
- HDL 11-26-2025
- TNGX 11-04-2025
- Dividend Yield
- HDL N/A
- TNGX N/A
- EPS Growth
- HDL 197.81
- TNGX N/A
- EPS
- HDL 0.09
- TNGX N/A
- Revenue
- HDL $805,433,000.00
- TNGX $66,501,000.00
- Revenue This Year
- HDL $11.22
- TNGX $20.41
- Revenue Next Year
- HDL $13.44
- TNGX N/A
- P/E Ratio
- HDL $21.28
- TNGX N/A
- Revenue Growth
- HDL 9.65
- TNGX 53.29
- 52 Week Low
- HDL $15.54
- TNGX $1.03
- 52 Week High
- HDL $30.00
- TNGX $9.70
- Technical
- Relative Strength Index (RSI)
- HDL 47.74
- TNGX 52.85
- Support Level
- HDL $16.81
- TNGX $7.49
- Resistance Level
- HDL $17.87
- TNGX $8.74
- Average True Range (ATR)
- HDL 0.22
- TNGX 0.64
- MACD
- HDL 0.05
- TNGX -0.03
- Stochastic Oscillator
- HDL 70.54
- TNGX 59.49
About HDL SUPER HI INTERNATIONAL HOLDING LTD. American Depositary Shares
Super Hi International Holding Ltd is an investment holding company and its subsidiaries are principally engaged in restaurant operations, delivery business, and sales of hot pot condiment products and food ingredients located in the overseas market outside Mainland China, Hong Kong, Macau, and Taiwan. It mission is to become a global integrated restaurant group, build the world's Chinese cuisine brand, and promote Chinese culinary heritage world-wide.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.